(Fighting against new crown pneumonia) British experts warn against being too optimistic about the new crown vaccine
China News Agency, London, October 28 (Gao Tianyin) Kate Bingham, chairman of the British Vaccine Working Group, warned on the 28th that the first generation of new coronavirus vaccines "may not be perfect" and people cannot be too optimistic.
Bingham said in an interview with the media that day, “The first-generation vaccines are likely to be imperfect. We should be prepared. They may not prevent infection, but reduce symptoms. Even then, they may not be effective for everyone. Effective or long-term effective."
Bingham recently published a similar opinion in the "Lancet" magazine, stating that in the history of medicine, no vaccine "has been so eagerly anticipated". "Vaccination is widely regarded as the only way to solve the current plight of the global new crown epidemic. "Strategy", "However, we simply do not know whether there will be a truly effective vaccine. We must prevent recklessness and excessive optimism."
Bingham believes that "the UK vaccine strategy is to build a diverse portfolio across different forms, so that the UK has the greatest opportunity to obtain safe and effective vaccines. We know and recognize a lot of vaccine information, and we are still not sure which vaccine. It will be successful".
British Secretary of the Environment George Eustice told the media that Bingham’s analysis “may be correct”, “to some extent vaccines will be the answer to the problem, but now exactly when will the vaccine be It’s too early to succeed."
Recently, a review report on coronavirus vaccine research in the British scientific community called for a standardized method to assess the effectiveness of all potential new coronavirus vaccines.
Dr. Susanne Hodgson, University of Oxford, UK, believes that “the adoption of a standardized method to measure the success of vaccines in clinical trials is very important for conducting meaningful controlled studies, and the most effective vaccine candidates will be further developed. Promote use."
It is reported that there are currently more than 200 candidate vaccines being developed around the world, of which 44 are undergoing clinical trials, and 9 vaccines are in the third stage of clinical trial evaluation.
(Finish)